FTC Slams Surescripts' E-Prescribing Networks, Says 'Web Of Loyalty Contracts' Blocks Competition
Surescripts maintained a monopoly on electronic prescription routing and eligibility markets through exclusive contracts with pharmacies and PBMs, complaint alleges.
You may also be interested in...
US Federal Trade Commission has mainly focused in pay-for-delay cases over the past decade, but pricing strategies are an emerging area of attention; industry is paying close attention to potential enforcement in biosimilar market.
Plaintiff Peter Lurie, former US FDA associate commissioner, expects results of hundreds of clinical trials of approved drugs will become available under ruling against HHS; co-plaintiff sought eteplirsen study data.